Results 21 to 30 of about 278,227 (245)

Update on the surgical management of Graves’ orbitopathy

Frontiers in Endocrinology, 2023
Graves’ orbitopathy (GO) is a complex autoimmune disorder of the orbit that causes the eye to appear disfigured. GO is typically associated with Graves’ disease, an inflammatory autoimmune condition that is caused by thyrotropin receptor autoantibodies ...
Joonyoung Baeg, Hannah Choi, Charm Kim, Hyuna Kim, S. Jang   +4 more
semanticscholar   +1 more source

Deep learning-based diagnosis of disease activity in patients with Graves’ orbitopathy using orbital SPECT/CT

European Journal of Nuclear Medicine and Molecular Imaging, 2023
Orbital [99mTc]TcDTPA orbital single-photon emission computed tomography (SPECT)/CT is an important method for assessing inflammatory activity in patients with Graves’ orbitopathy (GO).
Ni Yao, Longxi Li, Zhengyuan Gao, Chen Zhao, Yanting Li, Chuang Han, Jiaofen Nan, Zelin Zhu, Yi Xiao, Fubao Zhu, Min Zhao, Weihua Zhou   +11 more
semanticscholar   +1 more source

Long-term outcome of Graves' orbitopathy following treatment with sirolimus. [PDF]

J Endocrinol Invest
Sirolimus was found to be associated with a better outcome of Graves’ orbitopathy (GO) at 24 weeks compared to methylprednisolone. We conducted a retrospective study to investigate its efficacy and safety over a longer period.
Comi S, Cosentino G, Lanzolla G, Menconi F, Maglionico MN, Posarelli C, Latrofa F, Rocchi R, Figus M, Santini F, Marinò M.   +10 more
europepmc   +2 more sources

Management of patients with Graves' disease and orbital involvement: role of spectral domain optical coherence tomography [PDF]

, 2018
PURPOSE: To investigate the role of choroidal thickness evaluation with spectral domain optical coherence tomography (SDOCT) and enhanced depth imaging (EDI) technique in the management of patients with Graves' disease and orbitopathy (GO).
Bruscolini, A, Gharbiya, M, La Cava, M, Lambiase, A, Marenco, M, Nardella, C, Restivo, L, Sacchetti, M   +7 more
core   +1 more source

Tocilizumab improves clinical outcome in patients with active corticosteroid-resistant moderate-to-severe Graves’ orbitopathy: an observational study

Frontiers in Endocrinology, 2023
Background Graves’ orbitopathy (GO) is an autoimmune disorder affecting the orbital fat and muscles. A significant role of IL-6 in the pathogenesis of GO has been described and tocilizumab (TCZ), an IL-6 inhibitor targeting IL-6R has been given in some ...
G. Boutzios, S. Chatzi, A. Goules, Areti Mina, G. Charonis, P. Vlachoyiannopoulos, A. Tzioufas   +6 more
semanticscholar   +1 more source

Not All Orbitopathy Is Graves’: Discussion of Cases and Review of Literature

Frontiers in Endocrinology, 2017
IntroductionGraves’ orbitopathy is the extra thyroidal manifestation of Graves’ disease and the most common cause of exophthalmos. It is also known as thyroid-associated orbitopathy (TAO) as it occasionally occurs in euthyroid or hypothyroid patients ...
Neeraja Boddu, Maliha Jumani, Vibhor Wadhwa, Gitanjali Bajaj, Fred Faas   +4 more
doaj   +1 more source

TSH receptor specific monoclonal autoantibody K1‐70TM targeting of the TSH receptor in subjects with Graves' disease and Graves' orbitopathy—Results from a phase I clinical trial

Clinical Endocrinology, 2022
In Graves' disease (GD), autoantibodies to the thyroid stimulating hormone receptor (TSHR) cause hyperthyroidism. The condition is often associated with eye signs including proptosis, oedema, and diplopia (collectively termed Graves' orbitopathy [GO ...
J. Furmaniak, J. Sanders, P. Sanders, Yang Li, Bernard Rees Smith   +4 more
semanticscholar   +1 more source

The role of hormonal imbalance in the development of autoimmune dacryoadenitis in endocrine orbitopathy

Oftalʹmologiâ, 2014
The authors analyzed the hormonal profile of patients with Graves’ disease and endocrine orbitopathy with or without autoimmune dacryoadenitis.
V. G. Likhvantseva, T. N. Safonova, O. A. Gontyurova, E. A. Rudenko, V. A. Vygodin   +4 more
doaj   +3 more sources

Rituximab Treatment in a Patient with Active Graves’ Orbitopathy and Psoriasis

Türk Oftalmoloji Dergisi, 2017
Management of Graves’ orbitopathy remains an important therapeutic challenge. Current therapeutic modalities are unsatisfactory in about one third of patients.
Tülay Şimşek, Nilgün Yıldırım, Belgin Efe, Nur Kebapçı   +3 more
doaj   +1 more source

Asymmetric Graves’ Orbitopathy

Frontiers in Endocrinology, 2020
Graves’ Orbitopathy (GO) is an autoimmune orbital disorder usually presenting as a sequala of autoimmune thyroid disease. The presence of GO is associated with increased psychological burden and, in severe cases may cause blindness.
Grigorios Panagiotou, Petros Perros
doaj   +1 more source